mGlide RCT: A Clinical Glide Path To Close the Guideline-to-Practice Gap In HTN Management
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03612271 |
Recruitment Status :
Recruiting
First Posted : August 2, 2018
Last Update Posted : November 16, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hypertension | Behavioral: mGlide | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 450 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Investigator) |
Primary Purpose: | Treatment |
Official Title: | mGlide RCT: A Clinical Glide Path To Close the Guideline-to-Practice Gap In HTN Management |
Actual Study Start Date : | March 1, 2019 |
Estimated Primary Completion Date : | December 31, 2022 |
Estimated Study Completion Date : | April 30, 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: mGlide Intervention
Participants will be educated on HTN and taught to self-monitor their BP. The transmitted BP will be used for adjustment of anti-HTN medications as it occurs in clinical practice.
|
Behavioral: mGlide
BP will be automatically transmitted to the providers. The transmitted BP will be used for adjustment of anti-HTN medications as it occurs in clinical practice. |
No Intervention: Clinical Care Comparison
Patients will be educated similar to intervention and taught self-monitoring of BP. Then they will be asked to follow up with primary care as usual.
|
- HTN control into guideline specified range [ Time Frame: 6 months ](SBP <140 mm Hg)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 85 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Stroke survivors (ischemic stroke or intra-parenchymal hemorrhage) or patients who have not had a stroke but carry a high risk of stroke or cardiovascular disease (CVD) events (>7.5% over 10 years) as defined by the AHA/ACC guideline on risk stratification9
- Diagnosis of uncontrolled HTN at the time of study enrollment (need not have stroke)
- Uncontrolled blood pressure (BP) defined as SBP >140 mm Hg at the last 2 clinic visits in the 6 months prior to the screening date. Alternatively, if a patient was discharged from the hospital in the 6 months prior to screening and does not have 2 clinic visits after hospital discharge, at least one hospital SBP in the last 2 days of the hospital stay must be >140 mm Hg. Screening of uncontrolled HTN will be based on Electronic Medical Record (EMR) BP data.
- Capable and willing to comply with the entire study protocol
- Able to give voluntary written informed consent
- English, Spanish or Hmong speaking
- Have a smart phone or mobile technology device (e.g. ipad) that can transmit BP from the BP monitor. iOS and Android Compatible. (iOS 7 or higher: iPhone 4 or higher, iPod touch 5th generation or higher, iPad 2nd generation or higher. Android 4.0 or higher.)
Exclusion Criteria:
- Unable or unwilling to give consent
- Any severe co-morbid illness including end stage kidney disease (ESRD), end stage liver disease (ESLD) or when life expectancy is less than 1 year or if primary care provider feels that medical complexity of the patient precludes clinical trial participation
- Unable to complete study tasks
- Any serious psychiatric illness that, in the opinion of the investigator, would interfere with subject treatment, assessment or compliance including significant delusional disorders such as schizophrenia and bipolar illness.
- Do not speak English, Spanish or Hmong

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03612271
Contact: Emily Vollbrecht | 612-626-7979 | vollb007@umn.edu |
United States, Minnesota | |
Epidemiology Clinical Research Center | Recruiting |
Minneapolis, Minnesota, United States, 55415 | |
Contact: Emily Vollbrecht |
Principal Investigator: | Kamakshi Lakshminarayan, MD, PhD | University of Minnesota |
Responsible Party: | University of Minnesota |
ClinicalTrials.gov Identifier: | NCT03612271 |
Other Study ID Numbers: |
STUDY00003494 1R01HL138332-01A1 ( U.S. NIH Grant/Contract ) |
First Posted: | August 2, 2018 Key Record Dates |
Last Update Posted: | November 16, 2022 |
Last Verified: | November 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Hypertension mHealth |
Hypertension Vascular Diseases Cardiovascular Diseases |